Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial

被引：0

作者：

Motzer, Robert J.

Penkov, Konstantin

Uemura, Hirotsugu

Campbell, Matthew T.

Kollmannsberger, Christian K.

Lee, Jae-Lyun

Venugopal, Balaji

Van Den Eertwegh, Alfonsus

Negrier, Sylvie

Gurney, Howard

Albiges, Laurence

Berger, Raanan

Haanen, John

Rini, Brian I.

Larkin, James

Schmidinger, Manuela

Sandner, Robin

Wang, Jing

Di Pietro, Alessandra

Choueiri, Toni K.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Private Med Inst, Euromed Serv, St Petersburg, Russia

[3] Kindai Univ, Dept Urol, Fac Med, Osaka, Japan

[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Genitourinary Med Oncol, Houston, TX USA

[5] British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[8] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[9] Univ Lyon, Lyon, France

[10] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia

[11] Inst Gustave Roussy, Villejuif, France

[12] Chaim Sheba Med Ctr, Ramat Gan, Israel

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] Royal Marsden Hosp NHS Fdn Trust, London, England

[16] Med Univ Vienna, Vienna, Austria

[17] Pfizer Inc, Collegeville, PA USA

[18] Pfizer Inc, Cambridge, MA USA

[19] Pfizer SRL, Milan, Italy

[20] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：1

共 50 条

[1] Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
Oya, M.
Motzer, R. J.
Choueiri, T. K.
Haanen, J. B. A. G.
Eto, M.
Uemura, H.
Venugopal, B.
Rini, B. I.
Miyake, H.
Albiges, L.
Schmidinger, M.
Tomita, Y.
Umeyama, Y.
Ellers-Lenz, B.
Hoffman, J.
Larkin, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1517 - S1518
[2] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Motzer, Robert J.
Robbins, Paul B.
Powles, Thomas
Albiges, Laurence
Haanen, John B.
Larkin, James
Mu, Xinmeng Jasmine
Ching, Keith A.
Uemura, Motohide
Pal, Sumanta K.
Alekseev, Boris
Gravis, Gwenaelle
Campbell, Matthew T.
Penkov, Konstantin
Lee, Jae Lyun
Hariharan, Subramanian
Wang, Xiao
Zhang, Weidong
Wang, Jing
Chudnovsky, Aleksander
di Pietro, Alessandra
Donahue, Amber C.
Choueiri, Toni K.
NATURE MEDICINE, 2020, 26 (11) : 1733 - +
[3] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer
Paul B. Robbins
Thomas Powles
Laurence Albiges
John B. Haanen
James Larkin
Xinmeng Jasmine Mu
Keith A. Ching
Motohide Uemura
Sumanta K. Pal
Boris Alekseev
Gwenaelle Gravis
Matthew T. Campbell
Konstantin Penkov
Jae Lyun Lee
Subramanian Hariharan
Xiao Wang
Weidong Zhang
Jing Wang
Aleksander Chudnovsky
Alessandra di Pietro
Amber C. Donahue
Toni K. Choueiri
Nature Medicine, 2020, 26 : 1733 - 1741
[4] Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Uemura, Motohide
Tomita, Yoshihiko
Miyake, Hideaki
Hatakeyama, Shingo
Kanayama, Hiro-omi
Numakura, Kazuyuki
Takagi, Toshio
Kato, Tomoyuki
Eto, Masatoshi
Obara, Wataru
Uemura, Hirotsugu
Choueiri, Toni K.
Motzer, Robert J.
Fujii, Yosuke
Kamei, Yoichi
Umeyama, Yoshiko
Di Pietro, Alessandra
Oya, Mototsugu
CANCER SCIENCE, 2020, 111 (03) : 907 - 923
[5] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
Eto, M.
Motzer, R. J.
Choueiri, T. K.
Haanen, J. B. A. G.
Oya, M.
Uemura, H.
Venugopal, B.
Rini, B. I.
Miyake, H.
Albiges, L.
Schmidinger, M.
Tomita, Y.
Umeyama, Y.
Ellers-Lenz, B.
Hoffman, J.
Larkin, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513
[6] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Motzer, Robert J.
Campbell, Matthew T.
Alekseev, Boris Y.
Uemura, Motohide
Kollmannsberger, Christian K.
Gravis, Gwenaelle
Bjarnason, Georg A.
Gurney, Howard
Chung, Jinsoo
Haanen, John B. A. G.
Rini, Brian I.
Larkin, James M. G.
Schmidinger, Manuela
Nole, Franco
Chudnovsky, Aleksander
Huang, Bo
Hariharan, Subramanian
di Pietro, Alessandra
Albiges, Laurence
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[7] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Albiges, Laurence
Haanen, John B. A. G.
Larkin, James M. G.
Uemura, Motohide
Pal, Sumanta K.
Gravis, Gwenaelle
Campbell, Matthew T.
Penkov, Konstantin
Lee, Jae-Lyun
Ching, Keith A.
Mu, Xinmeng Jasmine
Wang, Xiao
Zhang, Weidong
Wang, Jing
Chudnovsky, Aleksander
di Pietro, Alessandra
Robbins, Paul B.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Choueiri, Toni K.
Rini, Brian I.
Cosgriff, Thomas
Miyake, Hideaki
Vogelzang, Nicholas J.
Kannourakis, George
Mariani, Mariangela
Chiruzzi, Chiara
Albiges, Laurence
Haanen, John B.
Larkin, James
Atkins, Michael B.
Schmidinger, Manuela
Magazzu, Domenico
Di Pietro, Alessandra
Motzer, Robert J.
BJU INTERNATIONAL, 2016, 118 : 29 - 30
[9] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Penkov, K.
Haanen, J. B. A. G.
Rini, B. I.
Albiges, L.
Campbell, M. T.
Kollmannsberger, C. K.
Negrier, S.
Uemura, M.
Lee, J. L.
Gurney, H.
Berger, R.
Schmidinger, M.
Larkin, J.
Atkins, M. B.
Wang, J.
Robbins, P. B.
Chudnovsky, A.
Di Pietro, A.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
[10] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
Choueiri, Toni K.
Rini, Brian I.
Larkin, James M. G.
Bjarnason, Georg A.
Gravis, Gwenaelle
Gurney, Howard
Lee, Jae-Lyun
Keizman, Daniel
Haanen, John B. A. G.
Tomita, Yoshihiko
Uemura, Hirotsugu
Albiges, Laurence
Schmidinger, Manuela
Atkins, Michael B.
Mariani, Mariangela
Shnaidman, Michael
Di Pietro, Alessandra
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →